Larimar Therapeutics, Inc.
LRMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $73 | $28 | $24 | $38 |
| G&A Expenses | $18 | $14 | $12 | $12 |
| SG&A Expenses | $18 | $14 | $12 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $91 | $42 | $37 | $50 |
| Operating Income | -$91 | -$42 | -$37 | -$50 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $10 | $5 | $1 | -$0 |
| Pre-Tax Income | -$81 | -$37 | -$35 | -$51 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$81 | -$37 | -$35 | -$51 |
| % Margin | – | – | – | – |
| EPS | -1.32 | -0.84 | -1.33 | -2.93 |
| % Growth | -57.1% | 36.8% | 54.6% | – |
| EPS Diluted | -1.32 | -0.84 | -1.33 | -2.93 |
| Weighted Avg Shares Out | 61 | 44 | 26 | 17 |
| Weighted Avg Shares Out Dil | 61 | 44 | 26 | 17 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$91 | -$41 | -$36 | -$50 |
| % Margin | – | – | – | – |